Los Angeles Capital Management & Equity Research Inc. Acquires New Position in Tandem Diabetes Care Inc (TNDM)

Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of Tandem Diabetes Care Inc (NASDAQ:TNDM) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 7,070 shares of the medical device company’s stock, valued at approximately $449,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. PNC Financial Services Group Inc. acquired a new position in shares of Tandem Diabetes Care in the 4th quarter worth approximately $44,000. IFP Advisors Inc grew its position in shares of Tandem Diabetes Care by 78.4% in the 4th quarter. IFP Advisors Inc now owns 1,757 shares of the medical device company’s stock worth $66,000 after acquiring an additional 772 shares in the last quarter. Advisor Group Inc. grew its position in shares of Tandem Diabetes Care by 38.2% in the 4th quarter. Advisor Group Inc. now owns 2,351 shares of the medical device company’s stock worth $89,000 after acquiring an additional 650 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Tandem Diabetes Care in the 4th quarter worth approximately $125,000. Finally, Strs Ohio grew its position in shares of Tandem Diabetes Care by 580.0% in the 4th quarter. Strs Ohio now owns 3,400 shares of the medical device company’s stock worth $129,000 after acquiring an additional 2,900 shares in the last quarter. Hedge funds and other institutional investors own 81.50% of the company’s stock.

NASDAQ:TNDM opened at $62.16 on Tuesday. Tandem Diabetes Care Inc has a 12-month low of $9.34 and a 12-month high of $74.81. The company has a market cap of $3.74 billion, a P/E ratio of -24.38 and a beta of 0.63.



Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings data on Tuesday, April 30th. The medical device company reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.10). Tandem Diabetes Care had a negative net margin of 50.73% and a negative return on equity of 40.76%. The company had revenue of $66.00 million for the quarter, compared to analyst estimates of $47.55 million. During the same quarter in the prior year, the firm earned ($1.82) EPS. The company’s revenue for the quarter was up 141.9% compared to the same quarter last year. Equities analysts forecast that Tandem Diabetes Care Inc will post -0.99 earnings per share for the current fiscal year.

TNDM has been the subject of several research reports. Leerink Swann initiated coverage on Tandem Diabetes Care in a research report on Monday. They issued an “outperform” rating and a $83.00 target price for the company. UBS Group lifted their target price on Tandem Diabetes Care from $53.00 to $66.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 30th. ValuEngine lowered Tandem Diabetes Care from a “strong-buy” rating to a “buy” rating in a research report on Monday, April 1st. Robert W. Baird lifted their target price on Tandem Diabetes Care from $46.00 to $55.00 and gave the stock an “outperform” rating in a research report on Friday, February 15th. Finally, Stifel Nicolaus lifted their target price on Tandem Diabetes Care from $58.00 to $70.00 and gave the stock a “hold” rating in a research report on Wednesday, May 1st. Four investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Tandem Diabetes Care has an average rating of “Buy” and an average price target of $68.13.

In other Tandem Diabetes Care news, insider Kim D. Blickenstaff sold 200,000 shares of Tandem Diabetes Care stock in a transaction on Monday, March 11th. The stock was sold at an average price of $64.95, for a total transaction of $12,990,000.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP David B. Berger sold 2,000 shares of Tandem Diabetes Care stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $63.09, for a total value of $126,180.00. Following the sale, the executive vice president now directly owns 3,765 shares in the company, valued at approximately $237,533.85. The disclosure for this sale can be found here. Insiders have sold a total of 337,300 shares of company stock valued at $22,012,659 in the last 90 days. Insiders own 6.90% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Los Angeles Capital Management & Equity Research Inc. Acquires New Position in Tandem Diabetes Care Inc (TNDM)” was reported by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://dakotafinancialnews.com/2019/05/14/los-angeles-capital-management-equity-research-inc-acquires-new-position-in-tandem-diabetes-care-inc-tndm.html.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Recommended Story: Momentum Indicator: Relative Strength Index

Want to see what other hedge funds are holding TNDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tandem Diabetes Care Inc (NASDAQ:TNDM).

Institutional Ownership by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.